These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 21642014

  • 1. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
    Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR.
    Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
    [Abstract] [Full Text] [Related]

  • 2. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 3. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun 19; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 4. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
    Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators.
    Clin Gastroenterol Hepatol; 2010 Jul 19; 8(7):600-9. PubMed ID: 20117244
    [Abstract] [Full Text] [Related]

  • 5. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):228-38. PubMed ID: 17634458
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A, CDP870 Crohn's Disease Study Group.
    Gastroenterology; 2005 Sep 19; 129(3):807-18. PubMed ID: 16143120
    [Abstract] [Full Text] [Related]

  • 7. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
    Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ, PRECiSE 2 Study Investigators.
    Am J Gastroenterol; 2010 Jul 19; 105(7):1574-82. PubMed ID: 20234346
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P.
    Br J Dermatol; 2012 Jul 19; 167(1):180-90. PubMed ID: 22413944
    [Abstract] [Full Text] [Related]

  • 9. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun 19; 18(101):108-10. PubMed ID: 19637418
    [Abstract] [Full Text] [Related]

  • 10. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X.
    Clin Gastroenterol Hepatol; 2014 Mar 19; 12(3):423-31.e1. PubMed ID: 24184736
    [Abstract] [Full Text] [Related]

  • 11. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
    Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ.
    Aliment Pharmacol Ther; 2010 Aug 19; 32(3):384-93. PubMed ID: 20491747
    [Abstract] [Full Text] [Related]

  • 12. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, Davies O, Stahl HD, Alten R.
    Rheumatology (Oxford); 2012 Jul 19; 51(7):1226-34. PubMed ID: 22344576
    [Abstract] [Full Text] [Related]

  • 13. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
    Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.
    Am J Gastroenterol; 2009 Aug 19; 104(8):1976-83. PubMed ID: 19471252
    [Abstract] [Full Text] [Related]

  • 14. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.
    Aliment Pharmacol Ther; 2010 Jun 19; 31(12):1276-85. PubMed ID: 20298497
    [Abstract] [Full Text] [Related]

  • 15. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
    Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR, PRECiSE 4 Study Investigators.
    Clin Gastroenterol Hepatol; 2010 Aug 19; 8(8):696-702.e1. PubMed ID: 20363366
    [Abstract] [Full Text] [Related]

  • 16. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
    Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P.
    Aliment Pharmacol Ther; 2004 Dec 19; 20(11-12):1337-46. PubMed ID: 15606396
    [Abstract] [Full Text] [Related]

  • 17. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb 19; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 18. Certolizumab pegol for induction of remission in Crohn's disease.
    Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA, Watanabe N.
    Cochrane Database Syst Rev; 2019 Aug 29; 8(8):CD012893. PubMed ID: 31476018
    [Abstract] [Full Text] [Related]

  • 19. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
    Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ.
    Aliment Pharmacol Ther; 2011 Jan 29; 33(2):185-93. PubMed ID: 21083671
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
    Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P, Swiss IBDnet.
    Inflamm Bowel Dis; 2010 Jun 29; 16(6):933-8. PubMed ID: 20014021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.